Spirit of curiosity and pioneering

From its early beginnings, Heel has been driven by a spirit of curiosity and pioneering innovation. Established in Berlin in 1936, its founder Dr. Hans-Heinrich Reckeweg was a creative and inquisitive thinker. A physician and homeopath, he not only developed new medicines using purely natural substances. He also pioneered a therapeutic approach based on using those natural medicines to help the body activate its autoregulating mechanisms.

But Reckeweg wasn’t satisfied with just seeing that his medicines and therapies worked – he wanted to know why they did. Scientific research into natural medicine became an integral part of what Heel is about. Thanks to this research-driven focus and innovations in the development of products and therapeutic solutions, Heel has continued to grow and thrive: The company moved to Baden-Baden in southern Germany in 1954 and became part of DELTON AG in 1977.

Since then we have been on a steady path of growth and internationalization. From our headquarters in Baden-Baden (Germany), we cooperate with subsidiaries and distribution partners around the world. Our founder was convinced that natural medicine has a vital role to play in healthcare. His vision paved the way for one modern medicine – and we at Heel will continue to stay at the forefront of these developments.

  • 1936: Biologische Heilmittel GmbH is founded

    Biologische Heilmittel Heel GmbH is founded

    in Berlin/Germany, by Dr. Hans-Heinrich Reckeweg. Reckeweg is a medical doctor and pioneer: He is never satisfied with existing therapies, but is always looking for something better to treat his patients. His vision: „One day I will build the bridge between homeopathy and conventional medicine.“ He names the company HEEL, an acronym for HERBA EST EX LUCE – The medicinal plant draws its power from the sunlight.
    1936
  • 1937
    1937: Heel product portfolio grows

    Product portfolio grows, first medicines in tablet form

    Many new medicines are developed during the early years, some of which are still among Heel‘s most successful products. These include Angin-Heel®, Gripp-Heel® , Traumeel®, Husteel® and Klimakt-Heel®. The first medicines in tablet form, Diarrheel® and Engystol®, are also launched.
  • 1946: A new beginning for Heel in Triberg

    A new beginning for Heel in Triberg

    After World War II, both the Reckeweg family and Heel find a new home in Triberg in the Black Forest. Valuable formulas as well as homeopathic mother tinctures are rescued from the ruins of Berlin. Reckeweg re-establishes his private practice and the company is revived.
    1946
  • 1948
    1948: Reckeweg develops an innovative therapeutic concept

    Reckeweg develops an innovative therapeutic concept

    Reckeweg develops the concept of Homotoxicology, published in MMW. Reckeweg H-H. Austauschwirkung, Homotoxine und Krankheitsabschnitte an den Geweben der drei Keimblätter. 1952; (12): 549-556. The goal of Homotoxicology is to use the body‘s own ability to regulate itself. Many concept aspects can be validated today by current cutting-edge science.
  • 1954: Heel relocates to Baden-Baden

    Heel relocates to Baden-Baden

    Due to the inconvenient geographical location of Triberg, the company relocates to Baden-Baden. After the complicated relocation is completed, manufacturing recommences with 15 employees.
    1954
  • 1957
    1957: Heel-Symposia in Baden-Baden continue to grow

    Heel-Symposia in Baden-Baden continue to grow

    1948: Reckeweg holds the first Heel-Symposium at the Hotel Adler in Triberg. Over the years, the symposium becomes an established event for specialists. The number of attendees grows continuously – from around 60 participants in 1957, to 500 physicians a few years later.
  • 1959: First "Injeel" ampoule medicines

    First "Injeel" ampoule medicines

    Injeels (Injection remedies Heel) generally refer to a series of single-constituent homeopathic potencies in ampoules for injection.
    1959
  • 1963
    1963: New company headquarters open in Baden-Baden

    New company headquarters open in Baden-Baden

    Continuous growth makes it necessary to find a new and roomier location for the company. A property in Baden-Baden is bought in 1961 and Heel moves into its new headquarters in 1963. Friedrich Doerper, Reckeweg‘s son-in-law, joins the company.
  • 1968: "German Medical Journal" features Traumeel®

    "German Medical Journal" features Traumeel®

    The "Deutsches Medizin Journal" (German Medical Journal) is the first general medical journal to run a feature on Traumeel® and how it works. The article entitled "Using Traumeel® ointment in the orthopedic clinic" reports on a clinical study and the therapeutic success of Traumeel®.
    1968
  • 1969
    1969: Zeel® becomes the first homeopathically manufactured arthrosis medicine available

    Zeel® becomes the first homeopathically manufactured arthrosis medicine available

    The market launch of Zeel® is a milestone in the treatment of arthrosis with natural medicine.
  • 1977: Acquisition of Heel by the DELTON AG

    Acquisition of Heel by the DELTON AG

    The family-owned company is acquired by the DELTON AG from Bad Homburg. Together with the Logwin AG, Heel is one of the economic success factors of the DELTON AG today.
    1977
  • 1986
    1986: Scientific publication on the efficacy of Gripp-Heel® and Engystol®

    Scientific publication on the efficacy of Gripp-Heel® and Engystol®

    The "Arzneimittelforschung" (Drug Research) magazine publishes an article entitled "The influence of homeopathic products on the phagocytic capability of granulocytes" with study results from Heel's Gripp-Heel® and Engystol® medicines. The effect was studied through in-vitro tests and in controlled single-blind trials.
  • 1989: Clinical study demonstrates efficacy of Traumeel®

    Clinical study demonstrates efficacy of Traumeel® ointment

    The first double-blind, placebo-controlled clinical trial with Traumeel® yields impressive results: Compared to placebo, Traumeel® leads to a significant improvement in joint mobility and pain after acute ankle sprain compared to placebo.
    1989
  • 1998
    1998: Double-blind, randomized clinical study with Vertigoheel®

    Double-blind, randomized clinical study with Vertigoheel®

    An article published in the American Medical Association Journal "Archives of Otolaryngology - Head and Neck Surgery" compares in a study the effect of betahistine with that of the multi-component medicine Vertigoheel®. The study shows that Vertiogheel® is as effective as a standard therapy.
  • Heel workforce passes the 1,000 mark

    A committed staff is the key to success. The hiring of the 1,000th employee is not only a sign of Heel’s constant growth, but also of Heel's appeal as an employer.
    2002
  • 2003
    2003: Launch of Neurexan®

    Launch of Neurexan®

    Launch of Neurexan® for the treatment of sleep disorders and stress-related nervous agitation. Neurexan® rapidly gains a significant market share, becoming one of the most successful Heel medicines. It is currently the top natural medicine in the stress and sleep segment in Germany.
  • 2006: Traumeel sales exceed 8 million package units/year

    Traumeel sales exceed 8 million package units/year

    In 2006, more than 8 million package units/year of Traumeel® are sold for the first time. Traumeel® is successful in 50 markets worldwide and has become popular among top athletes and Olympic teams.
    2006
  • 2008

    Manufacturing capacity in Baden-Baden expands

    Heel builds a 1,800 m² extension onto its existing manufacturing plant in Baden-Baden, creating its own production facility for plant-based mother tinctures and substantially expanding its overall manufacturing capacity.
    Heel natural medicines are manufactured according to current pharmaceutical standards and fulfil the highest quality requirements.
  • 2009: Record number of 100 million ampoules is manufactured

    Record number of 100 million ampoules is manufactured

    Heel becomes the global market leader for homeopathically manufactured ampoules.
    2009
  • 2011
    2011: 75th anniversary

    75th anniversary

    75 years Biologische Heilmittel Heel GmbH.
  • 2012: TAASS study

    TAASS Study

    The Traumeel® in Acute Ankle Sprain Study (TAASS) confirms that Traumeel® (ointment and gel) is as effective as diclofenac gel for treating pain and restoring function in acute ankle sprain.
    2012
  • 2015
    MOZArT trial

    MOZArT trial presented at EULAR, Rome

    Clinical data released at the 2015 European League Against Rheumatism (EULAR) congress show that Heel‘s Traumeel® and Zeel® T have a statistically significant effect on osteoathritis knee pain after only three injections, lasting to the last point measured at 99 days. The effect of this treatment is comparable with other intra-articular treatments with a good safety profile.
    The MOZArT trial is the first double-blind, randomized, controlled trial to assess the efficacy and safety of intra-articular injections of Traumee® and Zeel® T compared with placebo.